Summary Of Key Responsibilities

Scoping program questions and developing modeling and simulation strategy for clinical programs. Analysis and reporting of population pharmacokinetic/pharmacodynamic, exposure-response, and disease progression models. Apply simulation methods to support dose selection, trial design, and Go/No-Go decisions. Effectively partner with clinical, biostatistics, DMPK, health economics, and regulatory departments. Participate in the preparation of reports/abstracts/manuscripts for publications and regulatory documents.

Qualifications

Education

Candidates with Ph.D. degree in pharmaceutics, pharmacokinetics, pharmacometrics, biostatistics, engineering disciples, and related quantitative fields.

Experience

At least 2-3 years of post-doctoral experience in pharmaceutical industry or regulatory agency. Experience representing application of pharmacometrics in drug development and hands-on modeling experience.

Special Skills/Abilities

Required skills:

• Strong proficiency in R programming, and in non-linear mixed effects modeling software like NONMEM.
• Good understanding of pharmacokinetic, pharmacodynamic principles and drug development.
• Experience with programming clinical data sets.
• Strong written and oral communication skills and interpersonal skills.

Desirable skills:

• Strong statistical understanding of hierarchical modeling of longitudinal continuous and non-continuous data.
• Understanding of application of Bayesian methods.
• Application and development of system pharmacology models.

Supervision

Motivated and collaborative individual who can function independently with minimal supervision. Candidate should be able to multi-task and prioritize to provide pharmacometric support to help advance portfolio. Travel may occasionally be required.

About Alnylam

Alnylam Pharmaceuticals is an EEO employer committed to an exciting, diverse, and enriching work environment. Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our Culture

Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

Commitment to Diversity

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.